Drugs / DHA EE
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04198805 | Jan 2020 → Sep 2022 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Naga P. Chalasani | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DHA EE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04198805 ↗ |
| Action | Activate | “Potential mechanisms for DHA's effects in NAFLD include the reduction of TG synthesis via activation of peroxisome proliferator-activated receptors (PPAR-α and γ)” NCT04198805 ↗ |